TFG anticorps

N° du produit ABIN7120305

Détail du produit anti-TFG anticorps

Antigène: TFG (Trk-Fused Gene (TFG))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TFG est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Purification: Immunogen affinity purified

Pureté: ≥95 % as determined by SDS-PAGE

Immunogène: TRK-fused gene

Isotype: IgG

Information d'application

Indications d'application: WB: 1:500-1:5000, IHC: 1:20-1:200, IF: 1:50-1:500

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

Date de péremption: 12 months

Détails sur TFG

Antigène: TFG (Trk-Fused Gene (TFG))

Autre désignation: TRK fused gene (TFG Produits)

Synonymes: anticorps wu:fb11c10, anticorps zgc:55342, anticorps zgc:77230, anticorps HMSNP, anticorps SPG57, anticorps TF6, anticorps TRKT3, anticorps AI173908, anticorps trk-fused gene, anticorps TRK-fused gene, anticorps Trk-fused gene, anticorps tfg, anticorps TFG, anticorps Tfg

Sujet: Synonyms:FLJ36137, Protein TFG, TF6, TFG, TRK fused gene, TRK fused gene protein, TRKT3 Background:Protein TFG(TRK-fused gene protein) plays a role in regulating phosphotyrosine-specific phosphatase-1 activity. Mutations in TFG may have important clinical relevance for current therapeutic strategies to treat metastatic melanoma. Defects in TFG are a cause of thyroid papillary carcinoma(TPC), a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Hereditary motor and sensory neuropathy with proximal dominant involvement(HMSN-P) is an autosomal-dominant neurodegenerative disorder characterized by widespread fasciculations, proximal-predominant muscle weakness, and atrophy followed by distal sensory involvement. Recent genetic investigation indicates that formation of TFG-containing cytoplasmic inclusions and concomitant mislocalization of TAR DNA-binding protein 43 kDa(TDP-43) underlie motor neuron degeneration in HMSN-P. Pathological overlap of proteinopathies involving TFG and TDP-43 highlights a new pathway leading to motor neuron degeneration.

Poids moléculaire: 50-55 kDa

UniProt: Q92734